Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study

Switching to bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) from other antiretroviral regimens is safe and effective for virologically suppressed people living with HIV (PLWH). The term virological suppression includes both low but detectable HIV viremia and undetectable HIV vir...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Monica Basso, Giuliana Battagin, Stefano Nicolè, Maria Cristina Rossi, Francesco Colombo, Nicole Pirola, Stefano Baratti, Silvia Storato, Federico Giovagnorio, Vincenzo Malagnino, Grazia Alessio, Antonio Vinci, Massimo Maurici, Loredana Sarmati, Saverio Giuseppe Parisi
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2023-08-01
Serie:	Viruses
Soggetti:	co-formulated bictegravir emtricitabine and tenofovir alafenamide experienced HIV-1-positive patients HIV RNA undetectability HIV RNA control prior to switch CD4+ nadir
Accesso online:	https://www.mdpi.com/1999-4915/15/8/1727
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!